09:46:10 Europe / Stockholm
Svenska | English

Lipum

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-28 Bokslutskommuniké 2024
2024-10-25 Kvartalsrapport 2024-Q3
2024-07-26 Kvartalsrapport 2024-Q2
2024-05-29 Ordinarie utdelning LIPUM 0.00 SEK
2024-05-28 Kvartalsrapport 2024-Q1
2024-05-28 Årsstämma 2024
2024-04-02 Extra Bolagsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-10-31 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-06-27 Extra Bolagsstämma 2023
2023-05-11 Ordinarie utdelning LIPUM 0.00 SEK
2023-05-10 Årsstämma 2023
2023-04-25 Kvartalsrapport 2023-Q1
2023-03-24 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-10-12 Extra Bolagsstämma 2022
2022-07-27 Kvartalsrapport 2022-Q2
2022-05-18 Kvartalsrapport 2022-Q1
2022-04-27 Ordinarie utdelning LIPUM 0.00 SEK
2022-04-26 Årsstämma 2022
2022-03-25 Bokslutskommuniké 2021
2021-12-22 Extra Bolagsstämma 2021
2021-11-26 Kvartalsrapport 2021-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Lipum är ett biofarmaceutiskt bolag. Bolaget är i klinisk fas och specialiserade på upptäckt och utveckling av nya behandlingar för kroniska inflammatoriska sjukdomar. Bolagets läkemedelskandidat är baserad på en antikropp som ämnar användas i behandlingar för att blockera en specifik molekyl i immunförsvaret. Läkemedelskandidaten är i klinisk fas med prekliniska data för reumatism. Bolaget utvärderar även andra inflammatoriska sjukdomar. Lipum har sin verksamhet i Umeå.
Lipum receives loan commitment of SEK 20 million
2024-05-06 09:00:00

Lipum AB (publ) has signed an agreement with Flerie Invest AB including a loan commitment of SEK 20 million. The agreement which has been signed on market terms, enters into force on 1 June 2024, has a term of 12 months and runs without collateral.

"We are in a very intense phase with the completion of the clinical phase 1 study as well as we intend to start the planning of a phase 2 study. At the same time, we run several preclinical initiatives where we need flexibility in optimizing the execution. With this loan commitment, we get a security to carry out the activities without unnecessary delay. I am very pleased with the support we receive from our major shareholder Flerie Invest ", says Ola Sandborgh, CEO of Lipum.

Contacts
Ola Sandborgh, CEO
ola.sandborgh@lipum.se
+46 72 218 80 21
Web: www.lipum.se

About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

This information is information that Lipum is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-05-06 09:00 CEST.

Attachments
Lipum receives loan commitment of SEK 20 million

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden